Analysis of the Drug Resistance of Carbapenem-Resistant Klebsiella pneumoniae in the China Antimicrobial Resistance Surveillance Trial Program, 2007–2018

Abstract

Objective: To analyze the drug resistance data of carbapenem-resistant Klebsiella pneumoniae (CRKP) collected in 19 tertiary hospitals in the China Antimicrobial Resistance Surveillance Trial Program from 2007 to 2018. Methods: According to the unified plan, clinical isolates of Klebsiella pneumoniae were collected from 19 tertiary hospitals in 19 cities in mainland China. The minimum inhibitory concentrations (MIC) were determined by a twofold agar dilution method, and antimicrobial susceptibility was established. The isolates were characterized by antimicrobial susceptibility testing, and their drug resistance data were analyzed. Results: In total, 302 strains of CRKP were screened from 3,671 strains of K. pneumoniae. The clinical isolation rate of CRKP increased from 0.9% to 19.9% in the past 12 years, and the isolation rate of CRKP in pediatric patients increased the fastest, to 24.7%. Along this period, the isolation rate in the intensive care unit was higher than that in other settings. The number of CRKP strains with imipenem and meropenem MIC ≤8 mg/L decreased from 63.6% to 11.7% and from 72.7% to 14.2%, respectively. Resistance to drugs that may be used to treat drug-resistant bacterial infections has increased to varying degrees, and CRKP has the lowest resistance rate to polymyxin B (<19.0%). Conclusion: Because the MIC of CRKP is increasing each year in China, carbapenems are less likely to be used as part of combined therapy to treat CRKP infections. It is difficult to obtain good therapeutic effects against CRKP infections with MICs that are too high. CRKP is still the most sensitive to polymyxin B in vitro, followed by tigecycline. Combination therapy may be the most effective current treatment for CRKP infection.